The main aim of the German Federal Government's health research programme is to be able to combat major widespread diseases more effectively. The Federal Ministry of Education and Research (BMBF) is creating the prerequisites for this by establishing the German Centers for Health Research (DZG) as long-term, equal partnerships of non-university research institutions with universities and university hospitals.
The six German Centers for Health Research work closely together to exchange experiences and use synergies of co-operation The goal of all of them is translation: a fast and effective transfer of research results into clinical application and medical care.
Center of expertise for medicinal chemistry (MedChem)
The MedChem Expertise Center supports medicinal-chemical advancement of significant candidate drugs in all German Centers for Health Research. Its goal is to optimize small molecule drug candidates for selected projects.
Together against the new coronavirus
WHO Solidarity Trial
The DZIF and DZL have assumed the role of coordinating the WHO Solidarity Trial in Germany. The World Health Organisation has selected four particularly promising agents or agent combos for testing in a clinical trial programme that is being conducted on thousands of patients in many countries. Specific tests have shown that these agents have efficacy against the new coronavirus and these drugs have already been approved for the treatment of other diseases such as HIV and malaria.
LEOSS – a European registry
The DZIF and the German Society of Infectious Diseases (DGI) have set up a European case registry which is to collect clinical data of patients with SARS-CoV-2 infection. A special feature of this new registry is that all the data collected will be made available to the scientific community for use in joint analyses. LEOSS is multilingual and is to be implemented across the entire EU.